CVN-766 is under clinical development by Cerevance and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CVN-766’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CVN-766 is under development for the treatment of anxiety disorders, schizophrenia and substance (Drug) abuse. The drug candidate is a selective antagonist of a receptor expressed in the mesolimbic and mesocortical systems. It is being developed based NETSseq technology. It is administered through oral route. It acts by targeting orexin 1 receptor (Ox1R).
Cerevance is a pharmaceutical company that strives to develop medicines for the treatment of neurological and psychiatric diseases. It is also developing preclinical and clinical programs for Parkinson’s disease, L-Dopa induced dyskinesia, cognitive impairment, neuroinflammation, and anxiety. The company harnesses its technology platform to reveal the molecular properties of each brain cell type in human tissue. Cerevance aims to develop new therapies targeting antibodies, small molecules, and other modalities. It is also measuring glial cells across the brain which plays a role in diseases involving neuro-inflammation. The company has presence in the US and the UK. Cerevance is headquartered in Boston, Massachusetts, the US.
For a complete picture of CVN-766’s drug-specific PTSR and LoA scores, buy the report here.